Amyloid imaging of dutch-type hereditary cerebral amyloid angiopathy carriers
Aaron P. Schultz
Reina W. Kloet
Hamid R. Sohrabi, Edith Cowan UniversityFollow
Louise van der Weerd
Sanneke van Rooden
Marieke J. H. Wermer
Laure Grand Moursel
Bart N. M. van Berckel
Samantha L. Gardener, Edith Cowan UniversityFollow
Kevin Taddei, Edith Cowan UniversityFollow
Anne M. Fagan
Tammie L. Benzinger
John C. Morris
Randall J. Bateman
Dominantly Inherited Alzheimer Network
M. Edip Gurol
Mark A. van Buchem
Ralph Martins, Edith Cowan UniversityFollow
Jasmeer P. Chhatwal
Steven M. Greenberg
Annals of Neurology
School of Medical and Health Sciences
This work was supported by the National Institute of Neurologic Diseases and Stroke (R01NS070834) and the Dominantly Inherited Alzheimer's Network (UF1AG032438), which is funded by the National Institute on Aging, the German Center for Neurodegenerative Diseases, and the Raul Carrea Institute for Neurological Research, with partial support from the Research and Development Grants for Dementia from the Japan Agency for Medical Research and Development and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute.
To determine whether amyloid imaging with the positron emission tomography (PET) agent Pittsburgh compound B (PiB) can detect vascular β‐amyloid (Aβ) in the essentially pure form of cerebral amyloid angiopathy associated with the Dutch‐type hereditary cerebral amyloid angiopathy (D‐CAA) mutation.
PiB retention in a cortical composite of frontal, lateral, and retrosplenial regions (FLR) was measured by PiB‐PET in 19 D‐CAA mutation carriers (M+; 13 without neurologic symptoms, 6 with prior lobar intracerebral hemorrhage) and 17 mutation noncarriers (M−). Progression of PiB retention was analyzed in a subset of 18 serially imaged individuals (10 asymptomatic M+, 8 M−). We also analyzed associations between PiB retention and cerebrospinal fluid (CSF) Aβ concentrations in 17 M+ and 11 M− participants who underwent lumbar puncture and compared the findings to PiB‐PET and CSF Aβ in 37 autosomal dominant Alzheimer disease (ADAD) mutation carriers.
D‐CAA M+ showed greater age‐dependent FLR PiB retention (p < 0.001) than M−, and serially imaged asymptomatic M+ demonstrated greater longitudinal increases (p = 0.004). Among M+, greater FLR PiB retention associated with reduced CSF concentrations of Aβ40 (r = −0.55, p = 0.021) but not Aβ42 (r = 0.01, p = 0.991). Despite comparably low CSF Aβ40 and Aβ42, PiB retention was substantially less in D‐CAA than ADAD (p < 0.001).
Increased PiB retention in D‐CAA and correlation with reduced CSF Aβ40 suggest this compound labels vascular amyloid, although to a lesser degree than amyloid deposits in ADAD. Progression in PiB signal over time suggests amyloid PET as a potential biomarker in trials of candidate agents for this untreatable cause of hemorrhagic stroke.
Neuroscience and neurorehabilitation